Infectious Diseases
Long-term Safety and Efficacy of Rabies Monoclonal Antibody and Vaccine for Post-Exposure Prophylaxis: Insights from a Phase 4 Trial in India
A phase 4 randomized trial demonstrates that combining rabies monoclonal antibody with vaccine in category 3 exposures is safe, immunogenic, and effective in preventing rabies up to one year post-exposure.
